Circulogene Theranostics

Founded in 2015 and headquartered in Birmingham, Alabama, Circulogene Theranostics is a commercial-stage diagnostics company focused on precision oncology. Its core technology is a proprietary liquid biopsy platform that combines next-generation sequencing (NGS) and PCR to detect DNA, RNA, MSI, and PD-L1 status from a blood draw, aiming to complement or circumvent invasive tissue biopsies. The company has served over 25,000 patients and recently expanded its offerings with a tissue-based CGP assay and an exclusive AI-powered blood test for lung nodule risk stratification, positioning it in the high-growth liquid biopsy and early cancer detection markets.

Proprietary liquid biopsy platform combining a proprietary cfDNA/cfRNA enrichment process with dual NGS and PCR analytical methodologies to provide comprehensive genomic profiling (DNA, RNA, MSI, PD-L1) from blood.

Circulogene competes in the crowded liquid biopsy CGP market against leaders like Guardant Health (Guardant360) and Foundation Medicine (FoundationOne Liquid CDx). Its differentiation lies in combined DNA/RNA/PD-L1 profiling and the LungLifeAI nodule test, but it faces competitors in early lung cancer detection (e.g., Freenome, Grail).